{
    "data": [
        {
            "id": "4230431",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-27T15:15:41-05:00",
                "isLockedPro": false,
                "commentCount": 56,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Will Survive Its Talc Problem, But Shares Are Still In Trouble",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "87856",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "2922",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4230431-johnson-and-johnson-will-survive-talc-problem-shares-are-still-in-trouble"
            }
        },
        {
            "id": "4229439",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-20T11:57:05-05:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Buy The Dip? A 2-Point Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "2199",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4229439-johnson-and-johnson-buy-dip-2-point-analysis"
            }
        },
        {
            "id": "4229179",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-19T09:21:29-05:00",
                "isLockedPro": false,
                "commentCount": 56,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Weak Sign",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "2026",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4229179-johnson-and-johnson-weak-sign"
            }
        },
        {
            "id": "4229164",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-19T08:25:00-05:00",
                "isLockedPro": false,
                "commentCount": 62,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I Had To Buy Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103125",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "2007",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4229164-why-i-to-buy-johnson-and-johnson"
            }
        },
        {
            "id": "4229110",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-18T22:22:53-05:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Safe Is Johnson & Johnson's Dividend?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "2015",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4229110-how-safe-is-johnson-and-johnsons-dividend"
            }
        },
        {
            "id": "4229103",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-18T19:57:14-05:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Caution Here",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "2057",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4229103-johnson-and-johnson-caution"
            }
        },
        {
            "id": "4228912",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-18T08:28:22-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Overblown Sell-Off On Bad News Brings Great Buying Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104882",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "1678",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4228912-johnson-and-johnson-overblown-sell-off-on-bad-news-brings-great-buying-opportunity"
            }
        },
        {
            "id": "4228705",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-17T09:47:36-05:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Do Johnson & Johnson And BP Have In Common?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "38631",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "1710",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4228705-what-johnson-and-johnson-and-bp-in-common"
            }
        },
        {
            "id": "4228691",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-17T09:29:11-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Proves Its Psoriasis Drug Can Be A Big Contender",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "1773",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4228691-johnson-and-johnson-proves-psoriasis-drug-can-be-big-contender"
            }
        },
        {
            "id": "4228665",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-17T07:25:31-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lawsuit Protection For Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "1772",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4228665-lawsuit-protection-for-johnson-and-johnson"
            }
        },
        {
            "id": "4228608",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-16T19:08:00-05:00",
                "isLockedPro": false,
                "commentCount": 67,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Reuters Ripped Off The Band-Aid",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104329",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "1618",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4228608-johnson-and-johnson-reuters-ripped-off-band-aid"
            }
        },
        {
            "id": "4228478",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-14T23:20:30-05:00",
                "isLockedPro": false,
                "commentCount": 170,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Should Investors Worry About The Latest In Johnson & Johnson's Talcum Case?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "50452",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "1566",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4228478-should-investors-worry-latest-in-johnson-and-johnsons-talcum-case"
            }
        },
        {
            "id": "4225981",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-03T13:44:31-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson And Johnson: Add This Family Company To Your Portfolio Family",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104912",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "22333",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4225981-johnson-and-johnson-add-this-family-company-to-your-portfolio-family"
            }
        },
        {
            "id": "4223176",
            "type": "article",
            "attributes": {
                "publishOn": "2018-11-19T07:53:21-05:00",
                "isLockedPro": false,
                "commentCount": 62,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Johnson & Johnson A Buy Here?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4223176-is-johnson-and-johnson-buy"
            }
        },
        {
            "id": "4221346",
            "type": "article",
            "attributes": {
                "publishOn": "2018-11-12T12:35:10-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pharma Remains The Key Debate For Johnson & Johnson, But Other Segments Showing Signs Of A Recovery",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78545",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "21666",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4221346-pharma-remains-key-debate-for-johnson-and-johnson-segments-showing-signs-of-recovery"
            }
        },
        {
            "id": "4214170",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-25T06:07:24-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson's Real Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103970",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4214170-johnson-and-johnsons-real-value"
            }
        },
        {
            "id": "4213832",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-24T11:35:57-04:00",
                "isLockedPro": false,
                "commentCount": 77,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Don't Sell Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102327",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238101",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4213832-dont-sell-johnson-and-johnson"
            }
        },
        {
            "id": "4212674",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-19T06:18:25-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Johnson & Johnson For Dividend Growth And Steady Defensive Earnings: Third-Quarter Report",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85096",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238125",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4212674-buy-johnson-and-johnson-for-dividend-growth-and-steady-defensive-earnings-third-quarter"
            }
        },
        {
            "id": "4212256",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-17T17:16:04-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Paying A Premium For Liability Risk",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4212256-johnson-and-johnson-paying-premium-for-liability-risk"
            }
        },
        {
            "id": "4211767",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-15T20:19:06-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Can Johnson & Johnson Rally After Earnings?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "45521",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4211767-can-johnson-and-johnson-rally-after-earnings"
            }
        },
        {
            "id": "4210693",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-09T11:36:52-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Focusing On The Process",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25228",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4210693-johnson-and-johnson-focusing-on-process"
            }
        },
        {
            "id": "4208591",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-27T11:04:17-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Now Is The Time To Buy Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103862",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "20266",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4208591-now-is-time-to-buy-johnson-and-johnson"
            }
        },
        {
            "id": "4207936",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-24T12:40:10-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Smart Money On Johnson & Johnson Vs. Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "205114",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4207936-smart-money-on-johnson-and-johnson-vs-pfizer"
            }
        },
        {
            "id": "4207868",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-24T09:30:29-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Looking For A Recession-Proof Stock? Look No Further Than Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103071",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "20087",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4207868-looking-for-recession-proof-stock-look-no-johnson-and-johnson"
            }
        },
        {
            "id": "4207634",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-21T15:39:44-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "There Is A More Important Question Than High P/E Ratios Affecting Dividends: Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4207634-is-important-question-high-p-e-ratios-affecting-dividends-johnson-and-johnson"
            }
        },
        {
            "id": "4207539",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-21T06:29:00-04:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy This Stock If You Are Afraid Of An Imminent Bear Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "38631",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "20018",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4207539-buy-this-stock-you-are-afraid-of-imminent-bear-market"
            }
        },
        {
            "id": "4206480",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-15T13:36:59-04:00",
                "isLockedPro": false,
                "commentCount": 160,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Here's Why Valuation Determines Total Dividend Payments For Overvalued Stocks: Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23179",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4206480-why-valuation-determines-total-dividend-payments-for-overvalued-stocks-johnson-and-johnson"
            }
        },
        {
            "id": "4205521",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-11T10:04:50-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Where Is The Path To Gains?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "45521",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4205521-johnson-and-johnson-where-is-path-to-gains"
            }
        },
        {
            "id": "4205257",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-10T10:05:30-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Vs. Pfizer: You Can't Go Wrong With Either Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102830",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4205257-johnson-and-johnson-vs-pfizer-you-cant-go-wrong-either-stock"
            }
        },
        {
            "id": "4203703",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-03T04:10:41-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Darzalex Is Growing Faster Than Revlimid, Particularly Outside The U.S.",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56012",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4203703-why-darzalex-is-growing-faster-revlimid-particularly-outside-u-s"
            }
        },
        {
            "id": "4203655",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-02T14:41:07-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend Champion Spotlight: Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "50452",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238353",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4203655-dividend-champion-spotlight-johnson-and-johnson"
            }
        },
        {
            "id": "4200722",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-20T18:43:51-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Breakout Alert: Buy Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "45521",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238406",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4200722-breakout-alert-buy-johnson-and-johnson"
            }
        },
        {
            "id": "4200206",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-17T16:26:18-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Trump Insurance For Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4200206-trump-insurance-for-johnson-and-johnson"
            }
        },
        {
            "id": "4198520",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-13T10:17:43-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Navigating Through Litigation Overhang",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "18507",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4198520-johnson-and-johnson-navigating-through-litigation-overhang"
            }
        },
        {
            "id": "4195697",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-07T09:43:00-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Headline Risk But Business Solid",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "18289",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4195697-johnson-and-johnson-headline-risk-business-solid"
            }
        },
        {
            "id": "4191130",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-27T09:25:36-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "J&J: Lawsuits And Dividend Safety",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102327",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4191130-j-and-j-lawsuits-and-dividend-safety"
            }
        },
        {
            "id": "4189771",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-25T05:49:28-04:00",
                "isLockedPro": false,
                "commentCount": 1053,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Janssen's History And Continuation Decision With Imetelstat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "91365",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "201164",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4189771-janssens-history-and-continuation-decision-imetelstat"
            }
        },
        {
            "id": "4189306",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-23T21:07:34-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "J&J Wants A Piece Of Gilead's HIV Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "17730",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4189306-j-and-j-wants-piece-of-gileads-hiv-market"
            }
        },
        {
            "id": "4189017",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-22T15:07:57-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson - Aristocrat Looks Appealing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238564",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4189017-johnson-and-johnson-aristocrat-looks-appealing"
            }
        },
        {
            "id": "4188121",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-18T15:15:21-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Johnson & Johnson Is An Attractive Investment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104579",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "17562",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4188121-why-johnson-and-johnson-is-attractive-investment"
            }
        },
        {
            "id": "4188043",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-18T11:23:28-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Raises Guidance, Now What?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4188043-johnson-and-johnson-raises-guidance-now-what"
            }
        },
        {
            "id": "4188025",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-18T10:24:52-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "This Dividend Aristocrat Just Posted 10% Sales And 15% EPS Growth - Is It A Buy Today?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4188025-this-dividend-aristocrat-just-posted-10-percent-sales-and-15-percent-eps-growth-is-buy-today"
            }
        },
        {
            "id": "4187694",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-18T08:10:00-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Wait For The Outcome",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104177",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4187694-johnson-and-johnson-wait-for-outcome"
            }
        },
        {
            "id": "4187870",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-17T17:13:51-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Wonder Of Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "33291",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4187870-wonder-of-johnson-and-johnson"
            }
        },
        {
            "id": "4187786",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-17T13:14:09-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Looks Too Cheap",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238579",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4187786-johnson-and-johnson-looks-too-cheap"
            }
        },
        {
            "id": "4187759",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-17T12:51:22-04:00",
                "isLockedPro": false,
                "commentCount": 78,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A $4.7 Billion Payout, And 9,000 Cases Pending - Is It Time To Panic?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4187759-4_7-billion-payout-and-9000-cases-pending-is-time-to-panic"
            }
        },
        {
            "id": "4187545",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-16T14:31:24-04:00",
                "isLockedPro": false,
                "commentCount": 97,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Trouble Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "17461",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4187545-johnson-and-johnson-trouble-ahead"
            }
        },
        {
            "id": "4187274",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-15T00:50:00-04:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Floodgates And Tidal Waves",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4187274-johnson-and-johnson-floodgates-and-tidal-waves"
            }
        },
        {
            "id": "4184372",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-27T21:54:19-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: A $144 Discounted Cash Flow Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103314",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "16850",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4184372-johnson-and-johnson-144-discounted-cash-flow-valuation"
            }
        },
        {
            "id": "4184081",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-26T15:29:03-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Will Johnson & Johnson's Pipeline Drugs Offset Sales Erosion To Upcoming Generics?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78545",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "16798",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4184081-will-johnson-and-johnsons-pipeline-drugs-offset-sales-erosion-to-upcoming-generics"
            }
        },
        {
            "id": "4183774",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-25T13:04:36-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Offers A Favorable Price For Long-Term Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101430",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "16739",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4183774-johnson-and-johnson-offers-favorable-price-for-long-term-investors"
            }
        },
        {
            "id": "4183101",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-21T11:09:21-04:00",
                "isLockedPro": false,
                "commentCount": 52,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Strong Company, But Won't Fit In Most Portfolios",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104525",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4183101-johnson-and-johnson-strong-company-wont-fit-in-portfolios"
            }
        },
        {
            "id": "4182754",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-20T04:54:46-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4182754-buy-johnson-and-johnson"
            }
        },
        {
            "id": "4181537",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-14T01:19:55-04:00",
                "isLockedPro": false,
                "commentCount": 96,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Recent Purchase: Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4181537-recent-purchase-johnson-and-johnson"
            }
        },
        {
            "id": "4181353",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-13T11:33:41-04:00",
                "isLockedPro": false,
                "commentCount": 104,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Recent Price Drop Offers Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102327",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4181353-johnson-and-johnson-recent-price-drop-offers-opportunity"
            }
        },
        {
            "id": "4180503",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-09T07:48:31-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: High-Quality Value Hiding In Plain Sight",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "36431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238676",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4180503-johnson-and-johnson-high-quality-value-hiding-in-plain-sight"
            }
        },
        {
            "id": "4180007",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-07T09:24:08-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Johnson & Johnson For Dividend Growth And 40% Upside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85096",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238682",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4180007-buy-johnson-and-johnson-for-dividend-growth-and-40-percent-upside"
            }
        },
        {
            "id": "4178656",
            "type": "article",
            "attributes": {
                "publishOn": "2018-06-01T07:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Do You Feel About Johnson & Johnson?: Part IV - Today's Editors' Picks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103932",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4178656-how-you-feel-johnson-and-johnson-part-iv-todays-editors-picks"
            }
        },
        {
            "id": "4178396",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-31T09:21:51-04:00",
                "isLockedPro": false,
                "commentCount": 185,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "5 Reasons This Legendary Dividend Blue Chip Could Crush The Market Over The Next Decade",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238696",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4178396-5-reasons-this-legendary-dividend-blue-chip-crush-market-over-next-decade"
            }
        },
        {
            "id": "4175756",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-21T04:16:21-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "J&J Gets Rid Of Drug For Alzheimer's, But Remains Strong With Oncology Business",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4175756-j-and-j-gets-rid-of-drug-for-alzheimers-remains-strong-oncology-business"
            }
        },
        {
            "id": "4174583",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-16T07:06:24-04:00",
                "isLockedPro": false,
                "commentCount": 90,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Can I Expect To Make If I Invest In Johnson & Johnson Today?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23179",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4174583-what-can-i-expect-to-make-i-invest-in-johnson-and-johnson-today"
            }
        },
        {
            "id": "4173014",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-11T15:16:04-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Waiting On The Wave",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4173014-johnson-and-johnson-waiting-on-wave"
            }
        },
        {
            "id": "4171930",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-11T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 173,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Retirement Strategy: Starting A Retirement Portfolio Today With A Core Dividend Growth Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24971",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4171930-retirement-strategy-starting-retirement-portfolio-today-core-dividend-growth-stock"
            }
        },
        {
            "id": "4171458",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-08T19:23:57-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Looks To Change The Scope Of Depression Treatment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "14974",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4171458-johnson-and-johnson-looks-to-change-scope-of-depression-treatment"
            }
        },
        {
            "id": "4168159",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-01T16:12:47-04:00",
                "isLockedPro": false,
                "commentCount": 1016,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "It's Illogical To Think That Johnson & Johnson Has Dropped Geron",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104411",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "197196",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4168159-illogical-to-think-johnson-and-johnson-dropped-geron"
            }
        },
        {
            "id": "4164690",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-23T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 252,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Retirement Strategy: Waiting For Some Good Buys? Here Are A Few",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24971",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4164690-retirement-strategy-waiting-for-good-buys-are"
            }
        },
        {
            "id": "4164678",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-22T19:43:11-04:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Sells Off After Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4164678-johnson-and-johnson-sells-off-after-earnings"
            }
        },
        {
            "id": "4164520",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-20T17:57:14-04:00",
                "isLockedPro": false,
                "commentCount": 87,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Rising Inflationary Expectations Cap Equities",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "51592",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4164520-rising-inflationary-expectations-cap-equities"
            }
        },
        {
            "id": "4164105",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-19T14:27:57-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Steady As She Goes",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4164105-johnson-and-johnson-steady-goes"
            }
        },
        {
            "id": "4164027",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-19T13:30:38-04:00",
                "isLockedPro": false,
                "commentCount": 807,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Reaffirms Geron's Imetelstat As Lead Oncology Pipeline Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "88736",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4164027-johnson-and-johnson-reaffirms-gerons-imetelstat-lead-oncology-pipeline-drug"
            }
        },
        {
            "id": "4163989",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-19T09:58:17-04:00",
                "isLockedPro": false,
                "commentCount": 86,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Going The Way Of IBM?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4163989-johnson-and-johnson-going-way-of-ibm"
            }
        },
        {
            "id": "4163786",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-18T14:01:43-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Good Start Of The Year But Valuation Is Still Not Cheap Enough",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102620",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4163786-johnson-and-johnson-good-start-of-year-valuation-is-still-not-cheap-enough"
            }
        },
        {
            "id": "4163587",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-17T18:35:54-04:00",
                "isLockedPro": false,
                "commentCount": 76,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "This Dividend King Just Smashed Analyst Expectations With 10%+ Earnings Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4163587-this-dividend-king-just-smashed-analyst-expectations-10-percent-earnings-growth"
            }
        },
        {
            "id": "4163376",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-17T01:52:20-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Is Zytiga Patent Loss Priced In?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4163376-johnson-and-johnson-is-zytiga-patent-loss-priced-in"
            }
        },
        {
            "id": "4159478",
            "type": "article",
            "attributes": {
                "publishOn": "2018-03-28T08:10:32-04:00",
                "isLockedPro": false,
                "commentCount": 172,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Now Is The Time To Buy The 2 Best Dividend-Paying Pharma Stocks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4159478-now-is-time-to-buy-2-best-dividend-paying-pharma-stocks"
            }
        },
        {
            "id": "4157858",
            "type": "article",
            "attributes": {
                "publishOn": "2018-03-20T15:27:28-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Dividend Hike Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "38631",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4157858-johnson-and-johnson-dividend-hike-ahead"
            }
        },
        {
            "id": "4157319",
            "type": "article",
            "attributes": {
                "publishOn": "2018-03-17T15:02:30-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: A Dividend King For Strong Returns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238817",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4157319-johnson-and-johnson-dividend-king-for-strong-returns"
            }
        },
        {
            "id": "4155775",
            "type": "article",
            "attributes": {
                "publishOn": "2018-03-13T02:17:16-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Versus Pfizer: Which One Is The Better Income Investment?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4155775-johnson-and-johnson-versus-pfizer-which-one-is-better-income-investment"
            }
        },
        {
            "id": "4155046",
            "type": "article",
            "attributes": {
                "publishOn": "2018-03-09T11:00:18-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Fairly Priced Based On 3 Valuation Approaches",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102830",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "13027",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4155046-johnson-and-johnson-fairly-priced-based-on-3-valuation-approaches"
            }
        },
        {
            "id": "4154049",
            "type": "article",
            "attributes": {
                "publishOn": "2018-03-07T02:44:02-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: The Iconic Health Care Brand Is Attractive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24206",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238842",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4154049-johnson-and-johnson-iconic-health-care-brand-is-attractive"
            }
        }
    ]
}